The objective of this study is to estimate the change in baseline serum Hepatitis C RNA levels among Latino and Caucasian patients to demonstrate that the response rate is not different.

Condition	Treatment or Intervention	Phase
Hepatitis C	Drug: Pegylated Interferon alfa-2a (Pegasys) in combination with Ribavirin (Copegus)	Phase IV

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Infected with Hepatitis C virus
• Elevated ALT and AST levels
• Genotype 1

Exclusion Criteria:

• Previously treated with interferon/ribavirin
• NASH (nonalcoholic steatohepatitis)
• Positive for HIV
• Pregnancy
• Substance abuse

Please reference Study ID Number: RLI-ML18179      973-235-5000 
or      800-526-6367 (FOR US ONLY) 

Arizona
      Scottsdale,  Arizona,  85259,  United States; Not yet recruiting
      Tucson,  Arizona,  85712,  United States; Recruiting
California
      Anaheim,  California,  92801,  United States; Recruiting
      Ventura,  California,  93003,  United States; Recruiting
      San Bernadino,  California,  92404,  United States; Recruiting
      San Diego,  California,  92103,  United States; Not yet recruiting
      Redlands,  California,  92373,  United States; Recruiting
      San Diego,  California,  92161,  United States; Not yet recruiting
      Lancaster,  California,  93534,  United States; Recruiting
      Stanford,  California,  94305,  United States; Recruiting
      Fresno,  California,  93702,  United States; Not yet recruiting
Florida
      Miami,  Florida,  33136,  United States; Recruiting
      Miami,  Florida,  33136,  United States; Recruiting
      North Miami,  Florida,  33162,  United States; Recruiting
      Boca Raton,  Florida,  33428,  United States; Recruiting
Illinois
      Chicago,  Illinois,  60637,  United States; Recruiting
      Chicago,  Illinois,  60612,  United States; Recruiting
Indiana
      Indianapolis,  Indiana,  46202,  United States; Recruiting
Louisiana
      New Orleans,  Louisiana,  70112,  United States; Recruiting
Maryland
      Baltimore,  Maryland,  21205,  United States; Not yet recruiting
Massachusetts
      Framingham,  Massachusetts,  01702,  United States; Recruiting
Missouri
      St. Louis,  Missouri,  63110,  United States; Recruiting
New York
      Bayside,  New York,  11358,  United States; Recruiting
      Brooklyn,  New York,  11203,  United States; Not yet recruiting
      Setauket,  New York,  11733,  United States; Not yet recruiting
      New York,  New York,  10029,  United States; Recruiting
      Rochester,  New York,  14642,  United States; Recruiting
North Carolina
      Chapel Hill,  North Carolina,  27599,  United States; Recruiting
Pennsylvania
      Philadelphia,  Pennsylvania,  19107,  United States; Recruiting
      Philadelphia,  Pennsylvania,  19141,  United States; Not yet recruiting
Texas
      Galveston,  Texas,  77555,  United States; Not yet recruiting
      Houston,  Texas,  77030,  United States; Recruiting
      San Antonio,  Texas,  78258,  United States; Recruiting
      Fort Sam Houston,  Texas,  78234,  United States; Recruiting
      Forth Worth,  Texas,  76107,  United States; Not yet recruiting
      Houston,  Texas,  77030,  United States; Recruiting
Puerto Rico
      Santurce,  00909,  Puerto Rico; Recruiting

Study ID Numbers:  ML18179
Record last reviewed:  April 2005
Last Updated:  April 6, 2005
Record first received:  April 6, 2005
ClinicalTrials.gov Identifier:  NCT00107653
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08